This Viewpoint describes the US Food and Drug Administration’s intended label updates and removal of black box warnings for menopausal hormone therapy based on current evidence.
No takes yet. Share an insight, caveat, or question.
Makary et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: